SB 228357

a neuroleptic with equivalent or higher antagonist affinity for 5-HT2 than for dopamine D2 receptor

Also Known As:

1-5(-fluoro-3-(3-pyridyl)phenyl-carbamoyl)-5-methoxy-6-trifluoromethylindoline; SB-228357; SB228357

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

1.	Catalepsy 02/01/1999 - "The selective 5-HT2C/2B receptor antagonist, SB-228357 (0.32-10 mg kg(-1) p.o.) significantly reversed haloperidol-induced catalepsy whereas the 5-HT2A and 5-HT2B receptor antagonists, MDL-100907 (0.003-0.1 mg kg(-1) p.o.) and SB-215505 (0.1-3.2 mg kg(-1) p.o.) respectively did not reverse haloperidol-induced catalepsy. "